M. Dror Michaelson

Harvard University — United States

Medicine · Health Sciences

65h-index28.4kcitations284works21.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(172), Renal and related cancers(66), Cancer Genomics and Diagnostics(63), Prostate Cancer Treatment and Research(43), Bladder and Urothelial Cancer Treatments(39)

Publications284 total

Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
Open pilot of a culturally responsive, cognitive-behavioral intervention (PROWESS) for Black and Latino men receiving androgen deprivation therapy for prostate cancer.
Journal of Clinical Oncology·2025
Circulating tumor cell RNA biomarker for bavdegalutamide (ARV-110) in metastatic castration-resistant prostate cancer without AR T878/H875 mutations.
Journal of Clinical Oncology·2025· 1 cited
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
The Lancet Oncology·2025· 15 cited
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
Journal of Clinical Oncology·2024· 19 citedOpen Access
1994P Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
Annals of Oncology·2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
The Lancet Oncology·2024· 65 citedOpen Access
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712
European Urology Oncology·2024· 1 citedOpen Access
Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate Cancer
Journal of the American Society of Echocardiography·2024· 1 citedOpen Access
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Journal of the National Comprehensive Cancer Network·2024· 129 cited
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer
Radiotherapy and Oncology·2024· 5 citedOpen Access
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
European Journal of Cancer·2023· 24 cited
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma
Annals of Oncology·2023· 77 citedOpen Access
LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)
Annals of Oncology·2023· 13 citedOpen Access
2360O The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)
Annals of Oncology·2023· 4 citedOpen Access
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
European Urology Oncology·2023· 8 citedOpen Access
Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.
Journal of Clinical Oncology·2023· 1 cited
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
The Lancet Oncology·2023· 224 cited
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Journal of Clinical Oncology·2023· 164 cited
Data from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
2023Open Access
page 1 of 15Next →

Frequent Co-authors

Robert J. Motzer(28), Toni K. Choueiri(15), Thomas E. Hutson(13), Brian I. Rini(13), Ronald M. Bukowski(12), Robert A. Figlin(9), George Wilding(9), Bruce G. Redman(9), Jeffrey A. Sosman(8), Neeraj Agarwal(8), Piotr Tomczak(7), Sindy T. Kim(7), Charles M. Baum(7), Thomas Olencki(7), Brian A. Costello(7), Ithaar Derweesh(7), Steven Hancock(7), Elaine T. Lam(7), Clayton Lau(7), Elizabeth R. Plimack(7)